OREANDA-NEWS.  September 09, 2013. The Federal Antimonopoly Service (FAS Russia) received a letter from TEVA PHARMACEUTICAL INDUSTRIES LIMITED, which reported executing the warning issued by FAS on 16th August 2013.

The warning concerned TEVA’s supplies of “Compaxone-TEVA” (International Non-Proprietary Name: Glatiramer acetate) to “BIOTEK” MFPDK” CJSC so the company would executes the government contract for supplying the drug for multiple-sclerosis patients concluded with the Ministry of Health of the Russian Federation.

TEVA executed the warning within the designated period by signing an additional agreement to the contract and completing supplying the necessary quantity of “Compaxone-TEVA” to “BIOTEK” MFPDK” CJSC.

“FAS positively evaluates TEVA’s actions towards executing the warning and in all similar cases will monitor supplies of medicines till they are received by patients”, commented Deputy Head of FAS Andrey Kashevarov.